+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are studying the pharmacokinetics PK and safety of ublituximab given as a subcutaneous SC injection in people with relapsing multiple sclerosis MS. The study evaluates how the drug behaves in the body when injected at different sites and compares the bioavailability when administered by a prefilled pen versus a syringe. This Phase 2 trial is focused on treatment and aims to understand the best method of delivering ublituximab subcutaneously. Participants will receive ublituximab SC either at one of three different injection sites using a syringe or via a prefilled pen. The study randomly assigns participants to receive the drug using either the prefilled pen or the syringe. The treatment period includes assessments up to 12 weeks for primary PK measures and up to 120 weeks for safety and plasma concentration monitoring. During the study, participants will have blood samples taken to measure drug levels and safety will be monitored by tracking any adverse events. They will also report their satisfaction with the injection method through questionnaires up to week 96. The main outcome measured is the area under the curve AUC of ublituximab at steady state by week 12, with longer follow-up to assess plasma concentrations and side effects. The total study duration extends up to nearly three years, ensuring extended safety and treatment evaluation.

Age: 18Years - 65YearsAll GendersPhase 2
44 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the implementation and impact of a distribution program for low dead-space syringes and needles LDSSN in multiple low- and middle-income countries including Armenia, Georgia, Tanzania, Egypt, Nigeria, Vietnam, India, Ukraine, and South Africa. The study aims to identify best practices for LDSSN distribution to improve acceptance and maintain high usage rates among people who inject drugs PWID. This observational research also explores community preferences and barriers related to LDSSN access and usage. The study involves three phases Phase 1 includes focus group discussions FGDs with PWID to present and discuss various LDSSN products and gather feedback to inform selection. Phase 2 consists of a 6-week pilot where participants can access selected LDSSN products alongside usual needle and syringe program NSP services, followed by a second round of FGDs to reflect on experiences. In Phase 3, a selection of LDSSN products will be made available at NSP sites, while routine programmatic data and a cohort study with 240 participants per country 480 in Nigeria collect information on LDSSN uptake, HIV and HCV testing, and behavioral surveys over 18 months. Participants will be involved in surveys, HIV and HCV antibody testing at baseline, 6, 12, and 18 months, and ongoing access to usual services and LDSSN products. Data collection also includes routine program data on needle use and focus groups to assess acceptability and impact. Key informant interviews will evaluate feasibility and effectiveness, while mathematical modeling will estimate public health impact and cost-effectiveness of scaling up LDSSN distribution among PWID. The primary outcome measures the effectiveness of the community-informed LDSSN distribution program on increasing uptake over 18 months.

Age: 18Years +All Genders
9 locations